Table 1.
Study participant demographics and measurements at study entry
| Stage 1 or 2 during study (n = 54) | Progression to stage 3 (n = 11) | P | |
|---|---|---|---|
| Sex | 0.79 | ||
| Male | 25 (46.3) | 4 (36.4) | |
| Female | 29 (53.7) | 7 (63.6) | |
| Self-reported race | 0.67 | ||
| Asian | 1 (1.9) | 0 (0) | |
| Black or African American | 3 (5.6) | 1 (9.1) | |
| White | 50 (92.6) | 10 (90.9) | |
| Self-reported ethnicity | 1 | ||
| Hispanic or Latino | 1 (1.9) | 0 (0) | |
| Not Hispanic or Latino | 53 (98.1) | 11 (100) | |
| Mean (SD) age, years | 21.2 (11.9) | 15.0 (8.42) | 0.054 |
| Mean (SD) weight, kg | 66.0 (23.8) | 52.6 (22.8) | 0.097 |
| Mean (SD) BMI, kg/m2 | 23.5 (6.3) | 21.5 (6.2) | 0.35 |
| Mean (SD) body surface area, m2 | 1.72 (0.34) | 1.47 (0.38) | 0.07 |
| Type 1 diabetes stage | 0.86 | ||
| 1 | 31 (57.4) | 7 (63.6) | |
| 2 | 20 (37.0) | 4 (36.4) | |
| Unknown (no recent OGTT) | 3 (5.6) | 0 (0) | |
| Mean (SD) n of autoantibodies | 2.72 (1.5) | 4.27 (0.9) | <0.001 |
| Follow-up time, months | 7 (0–27) | 18 (15–43) | 0.14 |
| N of MRIs | 2 (1–3) | 3 (2–4.5) | 0.09 |
Data are given as n (%) or median (IQR) unless otherwise indicated.